T2 Biosystems Announces Issuance of Patent for Direct Detection Diagnostic Device and Methods
12/18/2012 9:05:50 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued patent number 8,334,693 (the ‘693 patent), “NMR device for detection of analytes”. The ‘693 patent covers the T2MR platform, which is used in T2 Bio’s T2Dx device for direct detection of analytes, including T2Candida, the lead product in T2 Bio’s pipeline. T2Candida is a whole blood diagnostic test for the rapid detection of five species of Candida, a fungal pathogen associated with sepsis and the fourth leading hospital-acquired infection in the United States.